These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34067981)

  • 1. Pseudoephedrine-Benefits and Risks.
    Głowacka K; Wiela-Hojeńska A
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kentucky pharmacists' opinions of the potential reclassification of pseudoephedrine as a legend drug.
    Monson KE; Freeman PR; Goodin AJ; Talbert J; Blumenschein K
    J Am Pharm Assoc (2003); 2014; 54(4):397-405. PubMed ID: 25063261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The advent of a new pseudoephedrine product to combat methamphetamine abuse.
    Brzeczko AW; Leech R; Stark JG
    Am J Drug Alcohol Abuse; 2013 Sep; 39(5):284-90. PubMed ID: 23968171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of urinary concentrations of pseudoephedrine and cathine after therapeutic administration of pseudoephedrine-containing medications to healthy subjects: implications for doping control analysis of these stimulants banned in sport.
    Barroso O; Goudreault D; Carbó Banús ML; Ayotte C; Mazzoni I; Boghosian T; Rabin O
    Drug Test Anal; 2012 May; 4(5):320-9. PubMed ID: 21548139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Problems of the use of pseudoephedrine by athletes.
    Pokrywka A; Tszyrsznic W; Kwiatkowska DJ
    Int J Sports Med; 2009 Aug; 30(8):569-72. PubMed ID: 19382058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of commercially available meth-deterrent pseudoephedrine hydrochloride products.
    Rahman Z; Aqueel MS; Korang-Yeboah M; Zidan AS; Chen J; Alayoubi AY; Cruz CN; Ashraf M
    Int J Pharm; 2020 Feb; 575():118909. PubMed ID: 31811923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysing pseudoephedrine/methamphetamine policy options in Australia using multi-criteria decision modelling.
    Manning M; Wong GT; Ransley J; Smith C
    Int J Drug Policy; 2016 Jun; 32():85-92. PubMed ID: 27179610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restricting the sale of pseudoephedrine to prevent methamphetamine production.
    Colker AC
    NCSL Legisbrief; 2005 Feb; 13(7):1-2. PubMed ID: 15726724
    [No Abstract]   [Full Text] [Related]  

  • 9. OTC, DTC, a stuffy nose, cocaine, and methamphetamine.
    Flaskerud JH; Strehlow AJ
    Issues Ment Health Nurs; 2008 Sep; 29(9):1041-4. PubMed ID: 18770107
    [No Abstract]   [Full Text] [Related]  

  • 10. Impacts of federal precursor chemical regulations on methamphetamine arrests.
    Cunningham JK; Liu LM
    Addiction; 2005 Apr; 100(4):479-88. PubMed ID: 15784062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of pseudoephedrine regulation at Australian pharmacies through Project Stop: A narrative review.
    Brookfield S; Gartner C
    Drug Alcohol Rev; 2024 Jan; 43(1):325-342. PubMed ID: 37963493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992-2007.
    Maxwell JC; Rutkowski BA
    Drug Alcohol Rev; 2008 May; 27(3):229-35. PubMed ID: 18368603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of controlling pseudoephedrine availability on methamphetamine-related emergency department visits.
    Hendrickson RG; Cloutier RL; Fu R
    Acad Emerg Med; 2010 Nov; 17(11):1216-22. PubMed ID: 21175520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amphetamine and pseudoephedrine cross-tolerance measured by c-Fos protein expression in brains of chronically treated rats.
    Ruksee N; Tongjaroenbuangam W; Casalotti SO; Govitrapong P
    BMC Neurosci; 2008 Oct; 9():99. PubMed ID: 18834549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions.
    Cunningham JK; Liu LM
    Addiction; 2003 Sep; 98(9):1229-37. PubMed ID: 12930210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudoephedrine legislation decreases methamphetamine laboratory-related burns.
    Burke BA; Lewis RW; Latenser BA; Chung JY; Willoughby C
    J Burn Care Res; 2008; 29(1):138-40. PubMed ID: 18182911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficiency of extraction and conversion of pseudoephedrine to methamphetamine from tamper-resistant and non-tamper-resistant formulations.
    Presley B; Bianchi B; Coleman J; Diamond F; McNally G
    J Pharm Biomed Anal; 2018 Jul; 156():16-22. PubMed ID: 29684907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and evaluation of pseudoephedrine hydrochloride abuse-deterrent formulations using thermal modified rice starch.
    Sohn JS; Choi JS
    Int J Biol Macromol; 2021 Jul; 182():1248-1258. PubMed ID: 33992650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug trials for obstructive sleep apnea.
    Strohl KP
    J Clin Sleep Med; 2010 Apr; 6(2):124-6. PubMed ID: 20411687
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical effects and management of methamphetamine abuse.
    Romanelli F; Smith KM
    Pharmacotherapy; 2006 Aug; 26(8):1148-56. PubMed ID: 16863490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.